GlobeNewswire by notified

Pixium Vision gaining confidence in execution timeline of the PRIMAvera pivotal trial following first patient implantation in the UK

Share

Pixium Vision gaining confidence in execution timeline of the PRIMAvera pivotal trial following first patient implantation in the UK

  • Successful implantation of the first patient in the PRIMAvera study in the UK
  • Follows successful implantations in France and Germany
  • PRIMAvera read-out now expected around end-2023

Paris, France,December8, 2021 – 07.00 CET– Pixium Vision SA (Euronext Growth Paris - FR0011950641), a bioelectronics company that develops innovative bionic vision systems to enable patients who have lost their sight to live more independent lives, announces today the successful implantation of the first patient in the UK in the PRIMAvera pivotal trial in atrophic dry age-related macular degeneration (dry-AMD).

This follows the approval of the PRIMAvera study by the UK's Medicines and Healthcare Products Regulatory Agency and the opening of the first UK PRIMAvera clinical site at the Moorfields Eye Hospital in London. The PRIMAvera study aims to confirm the safety as well as the benefits provided by the Prima System and is the last clinical step before seeking market approval in Europe. The study was initiated in Q4 2020 in France, and the first patient was implanted in March 2021. Pixium Vision has since established additional clinical sites, implanted its first patient in Germany, and also plans to expand to additional clinical sites in Spain, the Netherlands, and Italy throughout H1 2022.

"We are very proud to be part of the expansion of the PRIMAvera pivotal trial, and we are keen to help bringing this innovative system giving bionic vision to patients in need," said Dr.Mahi Muqit, Consultant Ophthalmologist and Cataract and Vitreoretinal Surgeon at Moorfields Eye Hospital. "It was the first implantation of the Prima System in the UK andat Moorfields Eye Hospital, and I was pleased by the simplicity of the procedure, making me confident that after overcoming the small learning curve,retinal surgeons will feel comfortable conducting this procedure,which can be life-changing for patients. Now that the patient has been implanted, we look forward to observing the progress the patient will make over the coming months."

The PRIMAvera study design is based on the positive data generated in a French feasibility study, showing the ability of patients with dry AMD to improve visual acuity with the Prima System.

A total of 38 patients will be enrolled in the PRIMAvera study, an open-label, baseline-controlled, non-randomized, multi-center, prospective, single-arm pivotal trial. The primary efficacy endpoint is the proportion of subjects with an improvement of visual acuity of logMAR 0.2 or more from baseline to 12 months, and the primary safety endpoint is the number and severity of device and procedure-related serious adverse events at 12 months follow-up. The study will include three years of follow-up, with an assessment of the primary endpoints at 12 months after implantation.

While the PRIMAvera trial was initially expected to read-out in late 2022, longer than expected competent authority approvals due to COVID-19 have led to delayed openings of clinical centres. However, with the implantation of patients initiated at 7 sites in France, 6 in Germany and now the UK, Pixium anticipates the recruitment to complete by the end of 2022 leading to a read-out of the PRIMAvera study around the end of 2023.

About Pixium Vision

Pixium Vision is creating a world of bionic vision for those who have lost their sight, enabling them to regain visual perception and greater autonomy. Pixium Vision’s bionic vision systems are associated with a surgical intervention and a rehabilitation period. Prima System sub-retinal miniature photovoltaic wireless implant is in clinical testing for patients who have lost their sight due to outer retinal degeneration, initially for atrophic dry age-related macular degeneration (dry AMD). Pixium Vision collaborates closely with academic and research partners, including some of the most prestigious vision research institutions in the world, such as Stanford University in California, Institut de la Vision in Paris, Moorfields Eye Hospital in London, Institute of Ocular Microsurgery (IMO) in Barcelona, University hospital in Bonn, and UPMC in Pittsburgh, PA. The company is EN ISO 13485 certified and qualifies as “Entreprise Innovante” by Bpifrance.

For more information: To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page. http://www.pixium-vision.com/fr

Follow us on To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.@PixiumVision; To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.www.facebook.com/pixiumvision

To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.www.linkedin.com/company/pixium-vision

To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

Contacts

Pixium Vision
Offer Nonhoff
Chief Financial Officer
investors@pixium-vision.com
+33 1 76 21 47 68
Media Relations

LifeSci Advisors
Sophie Baumont
sophie@lifesciadvisors.com
+33 6 27 74 74 49
Investor Relations
LifeSci Advisors
Guillaume van Renterghem
gvanrenterghem@lifesciadvisors.com
+41 76 735 01 31

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Nordic American Tankers Ltd (NYSE: NAT) – Further Purchase of NAT shares by Board Member Alexander Hansson21.1.2022 16:32:14 CET | Press release

Friday, January 21, 2022 Dear Shareholders and Investors, Alexander Hansson, Board Member in Nordic American Tankers Ltd (NAT) and son of Herbjorn Hansson, the NAT Founder, Chairman and CEO, has today bought 50,000 shares in NAT at $ 1.557 per share. Following the transaction, Alexander Hansson privately owns 1,185,000 shares in NAT. As in the past, the Hansson family is the largest private shareholder in the company. Alexander Hansson commented: "I strongly believe in the future of NAT" Sincerely, Herbjorn Hansson Founder, Chairman & CEO Nordic American Tankers Ltd. www.nat.bm CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS Matters discussed in this press release may constitute forward-looking statements. The Private Securities Litigation Reform Act of 1995 provides safe harbor protections for forward-looking statements in order to encourage companies to provide prospective information about their business. Forward-looking statements include statements concerning plans, obje

CONDITIONS FOR RIKSBANK REVERSED AUCTIONS SEK TREASURY BILLS21.1.2022 16:20:00 CET | Press release

Bid procedure, 2022-01-26BillsSWEDISH T-BILL: SE0017232689. 2022-04-20 Bid date2022-01-26Bid times10.00-11.00 (CET/CEST) on the Bid dateRequested volume (corresponding nominal amount)SE0017232689: 2000 mln SEK +/-1000 mln SEK Highest permitted bid volume (corresponding nominal amount)SE0017232689: 2000 mln SEK per bid Lowest permitted bid volume (corresponding nominal amount)SEK 50 million per bidExpected allocation timeNot later than 11.15 (CET/CEST) on the Bid dateDelivery and payment date2022-01-28Delivery of billsTo the Riksbank's account in Euroclear Sweden AB's securities settlement system 1 4948 6383 Stockholm, 2022-01-21 This is a translation of the special terms and conditions published on www.riksbank.se. In the case of any inconsistency between the English translation and the Swedish language version, the Swedish language version shall prevail. Complete terms and conditions can be retrieved at www.riksbank.se.

CONDITIONS FOR RIKSBANK BID PROCEDURE KOMMUNINVEST BONDS21.1.2022 16:20:00 CET | Press release

Bid procedure, 2022-01-25BondsKOMMUNINVEST I SVERIGE: 2311. SE0010948240. 2023-11-13 KOMMUNINVEST I SVERIGE: 2611, SE0012569572, 2026-11-12 KOMMUNINVEST I SVERIGE: 2805, SE0015660139, 2028-05-12 BidsBids on interest and volume are entered via Bloomberg Bond Auction SystemBid date2022-01-25Bid times10.00-11.00Requested volume (corresponding nominal amount)2311: 500 mln SEK +/-250 mln SEK 2611: 500 mln SEK +/-250 mln SEK 2805: 500 mln SEK +/-250 mln SEK Highest permitted bid volume (corresponding nominal amount)2311: 500 mln SEK per bid 2611: 500 mln SEK per bid 2805: 500 mln SEK per bid Lowest permitted bid volume (corresponding nominal amount)SEK 50 million per bidExpected allocation timeNot later than 11.15 (CET/CEST) on the Bid dateDelivery and payment date2022-01-27Delivery of bondsTo the Riksbank's account in Euroclear Sweden AB's securities settlement system 1 4948 6383General Terms and ConditionsGeneral Terms and Conditions General Terms and Conditions för the Riksbank’s Purchase

CONDITIONS FOR RIKSBANK REVERSED AUCTIONS SEK GOVERNMENT BONDS21.1.2022 16:20:00 CET | Press release

Bid procedure, 2022-01-28BondsSWEDEN I/L BOND: 3109. SE0005703550. 2025-06-01 SWEDEN I/L BOND: 3114, SE0013748258, 2030-06-01 Bid date2022-01-28Bid times09.00-10.00 (CET/CEST) on the Bid dateRequested volume (corresponding nominal amount)3109: 500 mln SEK +/-250 mln SEK 3114: 500 mln SEK +/-250 mln SEK Highest permitted bid volume (corresponding nominal amount)3109: 500 mln SEK per bid 3114: 500 mln SEK per bid Lowest permitted bid volume (corresponding nominal amount)SEK 50 million per bidExpected allocation timeNot later than 10.15 (CET/CEST) on the Bid dateDelivery and payment date2022-02-01Delivery of bondsTo the Riksbank's account in Euroclear Sweden AB's securities settlement system 1 4948 6383 Stockholm, 2022-01-21 This is a translation of the special terms and conditions published on www.riksbank.se. In the case of any inconsistency between the English translation and the Swedish language version, the Swedish language version shall prevail. Complete terms and conditions can be

Avance Gas Holding Ltd - Enter into Time Charter Agreement for Avance Capella21.1.2022 14:33:03 CET | Press release

Bermuda, 21 January 2022 - Avance Gas Holding Ltd ("AGAS" or the "Company") announce that we have entered into a Time Charter Agreement for a period of 2 years for our second dual fuel VLGC, Avance Capella, to LPG & Ethylene Shipowner and LPG trader, Petredec. The vessel will commence the time charter shortly after delivery ex-yard in South Korea end of February 2022 and the time charter hire has a mechanism which gives both parties exposure to the spot market rate. This transaction is another step in executing on our strategy to increase our time charter portfolio while also maintaining access to the market upside. For further queries, please contact: Kristian Sørensen, CEO Tel: +47 22 00 48 00 Randi Navdal Bekkelund, CFO Tel: +47 22 00 48 00 About Avance Gas: Avance Gas operates in the global market for transportation of liquefied petroleum gas (LPG). The Company is one of the world's leading owners and operators of very large gas carrier (VLGC) and operates a fleet of thirteen ships

Proposals by the Nomination Board to the Annual General Meeting 2022 of Suominen21.1.2022 13:00:00 CET | Press release

Suominen Corporation's stock exchange release on January 21, 2022 at 2:00 p.m. EET Proposal on the number of the members, on the composition, and on the Chair of the Board of Directors The Nomination Board of Suominen Corporation’s shareholders proposes to the Annual General Meeting that the number of Board members remains unchanged and would be six (6). The Nomination Board proposes to the Annual General Meeting that Andreas Ahlström, Björn Borgman, Jaakko Eskola, Nina Linander and Laura Raitio would be re-elected as members of Suominen Corporation’s Board of Directors. Out of the current Board members, Sari Pajari-Sederholm has informed that she is not available as a candidate for the Board of Directors. In addition, the Nomination Board proposes that Aaron Barsness would be elected as a new member of the Board of Directors. Mr. Aaron Barsness (born 1973, BA (Biology and Environmental Studies), U.S. and Swedish citizen) currently works as the CMO of Fazer Group. He has held a number

Auriant Mining AB (publ.) publishes 12m 2021 operational update21.1.2022 11:20:00 CET | Press release

Highlights: In 12m 2021, total gold production amounted to 910.8 kg (29,283 oz), compared to 964.7 kg (31,014 oz) in 12m 2020, a decrease of 6%, or 53.9 kg (1,731 oz), but in line with the 2021 production plan; Hard rock gold production was 893.3 kg (28,720 oz), compared to 952.7 kg (30,629 oz) in 12m 2020, a decrease of 6%, or 59.4 kg (1,909 oz);Alluvial gold production amounted to 17.5 kg (563 oz), compared to 12.0 kg (386 oz) in 2020, an increase of 46%, or 5,5 kg (178 oz);12m 2021, total gold sales were 818.5 kg (26,316 oz), compared to 946.4 kg (30,428 oz) in 12m 2020, a decrease of 127.9 kg (4,112 oz), or 14%;428,300 tonnes of ore were processed with an average grade of 2.30 g/t;In 12m of 2021, the CIL plant operated for 8,004 hours at an increased throughput rate of 53.5 tonnes per working hour (>50 t/hour) and at the targeted recovery rate of 91.2%;458,500 tonnes of ore were mined in 12m 2021, compared to 387,200 tonnes in 12m 2020, an increase of 71,300 tonnes or 18%. Strippin